Gene · 4144
Papers1,624
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 1,624
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| RBM15-mediated the m6A modification of MAT2A promotes osteosarcoma cell proliferation, metastasis and suppresses ferroptosis. | Mol Cell Biochem | 2025 | 39527319 | PubTator, text mining | PubMed |
| H4K20me3-Mediated Repression of Inflammatory Genes Is a Characteristic and Targetable Vulnerability of Persister Cancer Cells. | Cancer Res | 2025 | 39476057 | PubTator, text mining | PubMed |
| Transmembrane Amino Acid Transporters in Shaping the Metabolic Profile of Breast Cancer Cell Lines: The Focus on Molecular Biological Subtype. | Curr Issues Mol Biol | 2024 | 39852119 | PubTator, text mining | PubMed |
| Modeling and predicting single-cell multi-gene perturbation responses with scLAMBDA. | bioRxiv | 2024 | 39677694 | PubTator, text mining | PubMed |
| Enhancing Radiofrequency Ablation for Hepatocellular Carcinoma: Nano-Epidrug Effects on Immune Modulation and Antigenicity Restoration. | Adv Mater | 2024 | 39548919 | PubTator, text mining | PubMed |
| MAT2B regulates the protein level of MAT2A to preserve RNA N6-methyladenosine. | Cell Death Dis | 2024 | 39353892 | PubTator, text mining | PubMed |
| Inhibition of MAT2A Impairs Skeletal Muscle Repair Function. | Biomolecules | 2024 | 39334864 | PubTator, text mining | PubMed |
| Modulation of m6A RNA modification by DAP3 in cancer cells. | Proc Natl Acad Sci U S A | 2024 | 39316047 | PubTator, text mining | PubMed |
SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S-adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumors. | MedComm (2020) | 2024 | 39309689 | PubTator, text mining | PubMed |
| MAT2A inhibition combats metabolic and transcriptional reprogramming in cancer. | Drug Discov Today | 2024 | 39306235 | PubTator, text mining | PubMed |
| MAT2A is essential for zygotic genome activation by maintaining of histone methylation in porcine embryos. | Theriogenology | 2024 | 39276507 | PubTator, text mining | PubMed |
| TRIM25 activates Wnt/β-catenin signalling by destabilising MAT2A mRNA to drive thoracic aortic aneurysm development. | Hum Mol Genet | 2024 | 39216871 | PubTator, text mining | PubMed |
| Organophosphorus S-adenosyl-L-methionine mimetics: synthesis, stability, and substrate properties. | Front Chem | 2024 | 39148665 | PubTator, text mining | PubMed |
| Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer. | Nat Commun | 2024 | 39107274 | PubTator, text mining | PubMed |
Mendelian randomization based on genome-wide association studies and expression quantitative trait loci, predicting gene targets for the complexity of osteoarthritis as well as the clinical prognosis of the condition. | Front Med (Lausanne) | 2024 | 38994346 | PubTator, text mining | PubMed |
| Genetic and Phenotypic Changes Related to the Development of mec-Independent Oxacillin Non-Susceptibility in ST8 Staphylococcus aureus Recovered after Antibiotic Therapy in a Patient with Bacteremia. | Antibiotics (Basel) | 2024 | 38927220 | PubTator, text mining | PubMed |
| Computer-aided design of a fluorescent MAT2A inhibitor for visualized cancer synthetic lethality. | Bioorg Chem | 2024 | 38924884 | PubTator, text mining | PubMed |
| Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy. | J Med Chem | 2024 | 38818879 | PubTator, text mining | PubMed |
| Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition. | Arch Toxicol | 2024 | 38755480 | PubTator, text mining | PubMed |
The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity. | Biochem Biophys Res Commun | 2024 | 38704890 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4144/papers?page=6